Nathella Pavan Kumar1, Kadar Moideen1, Shanmugam Sivakumar1, Pradeep A Menon1, Vijay Viswanathan2, Hardy Kornfeld3, Subash Babu4. 1. National Institutes of Health-NIRT-International Center for Excellence in Research, Chennai, India. 2. Prof. M. Viswanathan Diabetes Research Center, Chennai, India. 3. University of Massachusetts Medical School, Worcester, MA, USA. 4. National Institutes of Health-NIRT-International Center for Excellence in Research, Chennai, India; LPD, NIAID, NIH, MD, USA. Electronic address: sbabu@mail.nih.gov.
Abstract
BACKGROUND: Tuberculosis-diabetes co-morbidity (TB-DM) is characterized by increased inflammation with elevated circulating levels of inflammatory cytokines and other factors. Circulating angiogenic factors are intricately involved in the angiogenesis-inflammation nexus. METHODS: To study the association of angiogenic factors with TB-DM, we examined the systemic levels of VEGF-A, VEGF-C, VEGF-D, VEGF-R1, VEGF-R2, VEGF-R3 in individuals with either TB-DM (n = 44) or TB alone (n = 44). RESULTS: Circulating levels of VEGF-A, C, D, R1, R2 and R3 were significantly higher in TB-DM compared to TB individuals. Moreover, the levels of VEGF-A, C, R2 and/or R3 were significantly higher in TB-DM with bilateral or cavitary disease or with hemoptysis, suggesting an association with both disease severity and adverse clinical presentation. The levels of these factors also exhibited a significant positive relationship with bacterial burdens and HbA1c levels. In addition, VEGF-A, C and R2 levels were significantly higher (at 2 months of treatment) in culture positive compared to culture negative TB-DM individuals. Finally, the circulating levels of VEGF-A, C, D, R1, R2 and R3 were significantly reduced following successful chemotherapy at 6 months. CONCLUSION: Our data demonstrate that TB-DM is associated with heightened levels of circulating angiogenic factors, possibly reflecting both dysregulated angiogenesis and exaggerated inflammation. Published by Elsevier Ltd.
BACKGROUND:Tuberculosis-diabetes co-morbidity (TB-DM) is characterized by increased inflammation with elevated circulating levels of inflammatory cytokines and other factors. Circulating angiogenic factors are intricately involved in the angiogenesis-inflammation nexus. METHODS: To study the association of angiogenic factors with TB-DM, we examined the systemic levels of VEGF-A, VEGF-C, VEGF-D, VEGF-R1, VEGF-R2, VEGF-R3 in individuals with either TB-DM (n = 44) or TB alone (n = 44). RESULTS: Circulating levels of VEGF-A, C, D, R1, R2 and R3 were significantly higher in TB-DM compared to TB individuals. Moreover, the levels of VEGF-A, C, R2 and/or R3 were significantly higher in TB-DM with bilateral or cavitary disease or with hemoptysis, suggesting an association with both disease severity and adverse clinical presentation. The levels of these factors also exhibited a significant positive relationship with bacterial burdens and HbA1c levels. In addition, VEGF-A, C and R2 levels were significantly higher (at 2 months of treatment) in culture positive compared to culture negative TB-DM individuals. Finally, the circulating levels of VEGF-A, C, D, R1, R2 and R3 were significantly reduced following successful chemotherapy at 6 months. CONCLUSION: Our data demonstrate that TB-DM is associated with heightened levels of circulating angiogenic factors, possibly reflecting both dysregulated angiogenesis and exaggerated inflammation. Published by Elsevier Ltd.
Authors: Nathella P Kumar; Rathinam Sridhar; Dina Nair; Vaithilingam V Banurekha; Thomas B Nutman; Subash Babu Journal: Immunology Date: 2015-04 Impact factor: 7.397
Authors: W Matsuyama; T Hashiguchi; K Matsumuro; F Iwami; Y Hirotsu; M Kawabata; K Arimura; M Osame Journal: Am J Respir Crit Care Med Date: 2000-09 Impact factor: 21.405
Authors: B I Restrepo; S P Fisher-Hoch; J G Crespo; E Whitney; A Perez; B Smith; J B McCormick Journal: Epidemiol Infect Date: 2006-07-25 Impact factor: 2.451
Authors: Stefan H Oehlers; Mark R Cronan; Ninecia R Scott; Monica I Thomas; Kazuhide S Okuda; Eric M Walton; Rebecca W Beerman; Philip S Crosier; David M Tobin Journal: Nature Date: 2014-11-24 Impact factor: 49.962
Authors: Stellah G Mpagama; Kaushik Ramaiya; Troels Lillebæk; Blandina T Mmbaga; Marion Sumari-de Boer; Nyanda Elias Ntinginya; Jan-Willem Alffenaar; Scott K Heysell; Ib C Bygbjerg; Dirk L Christensen Journal: BMJ Open Date: 2021-04-28 Impact factor: 2.692
Authors: María B Arriaga; Farina Karim; Artur T L Queiroz; Mariana Araújo-Pereira; Beatriz Barreto-Duarte; Caio Sales; Mahomed-Yunus S Moosa; Matilda Mazibuko; Ginger L Milne; Fernanda Maruri; Carlos Henrique Serezani; John R Koethe; Marina C Figueiredo; Afrânio L Kritski; Marcelo Cordeiro-Santos; Valeria C Rolla; Timothy R Sterling; Alasdair Leslie; Bruno B Andrade Journal: Front Immunol Date: 2022-07-08 Impact factor: 8.786